A citation-based method for searching scientific literature

Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card, Quincy Chu. Lung Cancer 2021
Times Cited: 13







List of co-cited articles
34 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
30

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Keunchil Park, Eric B Haura, Natasha B Leighl, Paul Mitchell, Catherine A Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee,[...]. J Clin Oncol 2021
77
23

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
475
23

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Keith M Kerr, Frédéric Bibeau, Erik Thunnissen, Johan Botling, Aleš Ryška, Jürgen Wolf, Katarina Öhrling, Peter Burdon, Umberto Malapelle, Reinhard Büttner. Lung Cancer 2021
33
23

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
675
23

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
D Ross Camidge, Robert C Doebele, Keith M Kerr. Nat Rev Clin Oncol 2019
207
15

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
211
15

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
234
15


Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
112
15

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
44
15

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
52
15


Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, Amir Vajdi, Natalie Vokes, Lingzhi Hong, Jianjun Zhang, Michael Y Tolstorukov, Yvonne Y Li, Liam F Spurr,[...]. J Thorac Oncol 2022
22
15

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Ferdinandos Skoulidis, John V Heymach. Nat Rev Cancer 2019
254
15

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
15

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
Nadia Howlader, Gonçalo Forjaz, Meghan J Mooradian, Rafael Meza, Chung Yin Kong, Kathleen A Cronin, Angela B Mariotto, Douglas R Lowy, Eric J Feuer. N Engl J Med 2020
339
15

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
80
15

Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
Daniel Kazdal, Véronique Hofman, Petros Christopoulos, Marius Ilié, Albrecht Stenzinger, Paul Hofman. Genes Chromosomes Cancer 2022
4
50

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.
Denis Horgan, Giuseppe Curigliano, Olaf Rieß, Paul Hofman, Reinhard Büttner, Pierfranco Conte, Tanja Cufer, William M Gallagher, Nadia Georges, Keith Kerr,[...]. J Pers Med 2022
7
28


The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler. Cell Rep Med 2021
32
15

Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.
Tyler E Miller, Michael Yang, David Bajor, Judah D Friedman, Richard Y C Chang, Afshin Dowlati, Joseph E Willis, Navid Sadri. J Clin Pathol 2018
21
15


The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas.
Baharia Mograbi, Simon Heeke, Paul Hofman. Diagnostics (Basel) 2021
11
18

Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review.
Rossella Bruno, Gabriella Fontanini. Diagnostics (Basel) 2020
34
15

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
221
15

Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation.
Ernest Nadal, Simon Heeke, Jonathan Benzaquen, Noelia Vilariño, Arturo Navarro, Daniel Azuara, Mar Varela, Josiane Otto, Nuria Baixeras, David Shahbazian,[...]. JCO Precis Oncol 2020
2
100

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Marco H Hofmann, Daniel Gerlach, Sandra Misale, Mark Petronczki, Norbert Kraut. Cancer Discov 2022
8
25


Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
E Heitzer, D van den Broek, M G Denis, P Hofman, M Hubank, F Mouliere, L Paz-Ares, E Schuuring, H Sültmann, G Vainer,[...]. ESMO Open 2022
7
28

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
15

Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
Giancarlo Pruneri, Filippo De Braud, Anna Sapino, Massimo Aglietta, Andrea Vecchione, Raffaele Giusti, Caterina Marchiò, Stefania Scarpino, Anna Baggi, Giuseppe Bonetti,[...]. Pharmacoecon Open 2021
10
20

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Nathan A Pennell, Maria E Arcila, David R Gandara, Howard West. Am Soc Clin Oncol Educ Book 2019
110
15

Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
Yutaka Maeda, Tomoshi Tsuchiya, Haiping Hao, David H Tompkins, Yan Xu, Michael L Mucenski, Lingling Du, Angela R Keiser, Takuya Fukazawa, Yoshio Naomoto,[...]. J Clin Invest 2012
104
7

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
7

Understanding and targeting resistance mechanisms in NSCLC.
Julia Rotow, Trever G Bivona. Nat Rev Cancer 2017
424
7

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li,[...]. J Hematol Oncol 2016
201
7

CD74-NRG1 fusions in lung adenocarcinoma.
Lynnette Fernandez-Cuesta, Dennis Plenker, Hirotaka Osada, Ruping Sun, Roopika Menon, Frauke Leenders, Sandra Ortiz-Cuaran, Martin Peifer, Marc Bos, Juliane Daßler,[...]. Cancer Discov 2014
167
7

Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Andrew M Frederickson, Stella Arndorfer, Ina Zhang, Maria Lorenzi, Ralph Insinga, Ashwini Arunachalam, Thomas A Burke, George R Simon. Immunotherapy 2019
32
7


International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
7

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Jason C Chang, Michael Offin, Christina Falcon, David Brown, Brian R Houck-Loomis, Fanli Meng, Vasilisa A Rudneva, Helen H Won, Sharon Amir, Joseph Montecalvo,[...]. Clin Cancer Res 2021
15
7

Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients.
Lucia Kim, Kyu Ho Kim, Yong Han Yoon, Jeong Seon Ryu, Suk Jin Choi, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu. J Korean Med Sci 2012
21
7

Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies.
L Succony, D M Rassl, A P Barker, F M McCaughan, R C Rintoul. Cancer Treat Rev 2021
8
12

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
419
7


The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Christian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, Kazuhiko Nakagawa, Marianne Nicolson, Solange Peters, Martin Reck, Yi-Long Wu, Odd Terje Brustugun, Lucio Crinò,[...]. J Thorac Oncol 2017
136
7

Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity.
Chiyuki Okuda, Young Hak Kim, Kengo Takeuchi, Yosuke Togashi, Katsuhiro Masago, Yuichi Sakamori, Tadashi Mio, Michiaki Mishima. J Thorac Oncol 2011
4
25

IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Jacques Cadranel, Elisabeth Quoix, Laurence Baudrin, Pierre Mourlanette, Denis Moro-Sibilot, Jean-François Morere, Pierre-Jean Souquet, Jean-Charles Soria, Franck Morin, Bernard Milleron. J Thorac Oncol 2009
40
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.